Wedbush Increases Earnings Estimates for TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Wedbush boosted their FY2028 EPS estimates for TScan Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.46 for the year, up from their prior forecast of $0.40. Wedbush currently has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share.

Other research analysts have also issued reports about the company. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Trading Down 3.4 %

NASDAQ TCRX traded down $0.18 during trading hours on Thursday, hitting $5.07. The company’s stock had a trading volume of 10,004 shares, compared to its average volume of 246,218. The stock has a fifty day moving average of $5.34 and a 200 day moving average of $6.52. The company has a quick ratio of 7.77, a current ratio of 7.77 and a debt-to-equity ratio of 0.08. TScan Therapeutics has a twelve month low of $3.73 and a twelve month high of $9.69. The firm has a market capitalization of $268.56 million, a P/E ratio of -4.95 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative return on equity of 63.11% and a negative net margin of 1,188.88%.

Institutional Trading of TScan Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in TScan Therapeutics by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after buying an additional 20,000 shares during the last quarter. Great Point Partners LLC increased its position in shares of TScan Therapeutics by 8.0% in the third quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock valued at $5,062,000 after acquiring an additional 75,544 shares during the last quarter. abrdn plc raised its holdings in TScan Therapeutics by 27.2% during the third quarter. abrdn plc now owns 371,655 shares of the company’s stock worth $1,851,000 after acquiring an additional 79,511 shares in the last quarter. Marshall Wace LLP boosted its position in TScan Therapeutics by 60.8% during the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after purchasing an additional 116,316 shares during the last quarter. Finally, Tocqueville Asset Management L.P. bought a new position in TScan Therapeutics in the first quarter valued at approximately $1,685,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was bought at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at $221,200. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other TScan Therapeutics news, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now owns 4,716 shares of the company’s stock, valued at $27,258.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Barbara Klencke acquired 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average price of $5.53 per share, with a total value of $27,650.00. Following the completion of the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $221,200. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 15,000 shares of company stock valued at $82,550. 2.76% of the stock is owned by company insiders.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.